Overall survival (OS) update in ALTER 1202: Anlotinib as third-line or further-line treatment in relapsed small-cell lung cancer (SCLC)Y. Cheng,Q. Wang,K. Li, J. Shi,Y. Liu,L. Wu, B. Han, G. Chen, J. He, J. Wang, D. Lou,H. Yu,H. Qin, X-L. LiAnnals of Oncology(2019)引用 29|浏览54暂无评分AI 理解论文溯源树样例生成溯源树,研究论文发展脉络